Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 12, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £13.0199 per share.
- Transaction Volume: Ranged from 18 to 20 shares per individual executive.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly details routine acquisitions of shares under the Company's Share Reward Plan.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a compliance filing required to disclose specific insider transactions.
Important Facts for Investors
- Transaction Type: All reported transactions were acquisitions of Ordinary Shares under the Company's Share Reward Plan, consisting of partnership shares and matching shares.
- Executives Involved: Transactions were executed by 10 senior executives, including the CEO (Ms E Walmsley), CFO (Mr S Dingemans), and President of R&D (Dr P J T Vallance).
- Transaction Date: All transactions occurred on December 11, 2017.
- Exchange: Transactions were conducted on the London Stock Exchange (XLON).
- Volume: Individual transaction volumes were minimal (18 or 20 shares), indicating standard plan participation rather than significant open-market trading.